Fulvestrant 500mg in Patients With Advanced Breast Cancer
Fulvestrant 500mg in Patients With Advanced Breast Cancer
Metastatic Breast Cancer
DRUG: Fulvestrant
Incidence, nature and severity of all Adverse Events assessed by CTCAE V4.0, Incidence, nature and severity of all Adverse Events assessed by CTCAE V4.0, From date of randomization until the date of date of death from any cause or last visit, assessed up to 100 months.
ORR, Objective Response Rate, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.|CBR, Clinical Benefit Rate, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.|PFS, Progression Free Survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.|OS, Overall Survival, From date of randomization until the date of date of death from any cause or last visit, assessed up to 100 months.
A multicenter, prospective study real-world to evaluate the safety profile and effectiveness in Chinese patients who received Fulvestrant 500mg as first-line endocrine treatment for Advanced breast cancer